Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Glesby, Marshall J ^a   Albu, Jeanine ^b   Chiu, Ya Lin ^a   Ham, Kirsis ^a   Engelson, Ellen ^b   He, Qing ^b   Muthukrishnan, Varalakshmi ^b   Ginsberg, Henry N ^c   Donovan, Daniel ^c   Ernst, Jerry ^d   Lesser, Martin ^e   Kotler, Donald P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d ACRIA Center on HIV and Aging   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; FIBRIC ACID DERIVATIVE; FISH OIL; GLUCOSE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TESTOSTERONE; ZIDOVUDINE;

ABDOMINAL OBESITY; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BODY COMPOSITION; BREAST ENGORGEMENT; BREAST TENDERNESS; CARPAL TUNNEL SYNDROME; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; EVENING DOSAGE; FATIGUE; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WHOLE BODY MRI;

ABDOMINAL FAT; BLOOD GLUCOSE; BODY COMPOSITION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MALE; MIDDLE AGED; PLACEBOS; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES;

EID: 84876089766     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061160     Document Type: Article

References (45)

1. Grinspoon S, Carr A, (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62 352/1/48 [pii];10.1056/NEJMra041811 [doi].
2. Brown TT, Glesby MJ, (2012) Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 8: 11-21 nrendo.2011.151 [pii];10.1038/nrendo.2011.151 [doi].
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P, (1999) Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115.
4. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, et al. (2011) Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 53: 185-196 cir324 [pii];10.1093/cid/cir324 [doi].
5. Koutkia P, Canavan B, Breu J, Grinspoon S, (2005) Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 90: 32-38.
6. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, et al. (2001) Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86: 504-510.
7. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, et al. (2002) Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30: 379-391.
8. Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, et al. (2007) Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 45: 286-297.
9. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, et al. (2004) Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35: 239-252.
10. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson Met al, (2006) Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr 43: 378-380.
11. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, et al. (1997) Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100: 3149-3153 10.1172/JCI119870 [doi].
12. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, et al. (2008) Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 13: 67-76.
13. Tungsiripat M, Bejjani DE, Rizk N, O'Riordan MA, Ross AC, et al. (2010) Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24: 1291-1298 10.1097/QAD.0b013e328339e274 [doi].
14. Engelson ES, Kotler DP, Tan Y, Agin D, Wang J, et al. (1999) Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 69: 162-169.
15. Molarius A, Seidell JC, (1998) Selection of anthropometric indicators for classification of abdominal fatness-a critical review. Int J Obes Relat Metab Disord 22: 719-727.
16. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410.
17. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, et al. (2001) The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86: 3480-3487.
18. Steil GM, Murray J, Bergman RN, Buchanan TA, (1994) Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes 43: 1365-1371.
19. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, et al. (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003-1015 10.1089/152091503322641060 [doi].
20. Lukaski HC, Johnson PE, (1985) A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids. Am J Clin Nutr 41: 363-370.
21. Wong WW, Sheng HP, Morkeberg JC, Kosanovich JL, Clarke LL, et al. (1989) Measurement of extracellular water volume by bromide ion chromatography. Am J Clin Nutr 50: 1290-1294.
22. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163-170.
23. Iman R, (1982) Some Aspects of the Rank Transformation in Analysis of Variance Problems. Proceedings of the SAS User's Group Intl 7: 676-680.
24. Schulz KF, Altman DG, Moher D, (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7: e1000251 10.1371/journal.pmed.1000251 [doi].
25. Nielsen S, Moller N, Christiansen JS, Jorgensen JO, (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50: 2301-2308.
26. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC, (2001) Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 86: 5813-5818.
27. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, et al. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797-802.
28. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, et al. (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44: 2210-2219.
29. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, et al. (2008) Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 9: 254-268 C71241628474U500 [pii];10.1310/hct0904-254 [doi].
30. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, et al. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784-2791.
31. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, et al. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22: 908-912.
32. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, et al. (1999) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48: 1102-1107.
33. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, et al. (2001) Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract 54: 181-190.
34. Smith SR, de JL, Volaufova J, Li Y, Xie H, et al. (2005) Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54: 24-32 S0026049504003026 [pii].
35. Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR, (2007) Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. PLoS Clin Trials 2: e21 10.1371/journal.pctr.0020021 [doi].
36. Sheth SH, Larson RJ, (2010) The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 10: 183 1471-2334-10-183 [pii];10.1186/1471-2334-10-183 [doi].
37. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11: 39-50 J11410W13135W7W2 [pii];10.1310/hct1101-39 [doi].
38. Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, et al. (2005) A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19: 1279-1287.
39. Falutz J, Allas S, Blot K, Potvin D, Kotler D, et al. (2007) Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359-2370.
40. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, et al. (2010) Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95: 4291-4304 jc.2010-0490 [pii];10.1210/jc.2010-0490 [doi].
41. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, et al. (2010) Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 53: 311-322 10.1097/QAI.0b013e3181cbdaff [doi].
42. Bourg CA, Phillips BB, (2012) Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother 46: 282-289 aph.1Q400 [pii];10.1345/aph.1Q400 [doi].
43. Nissen SE, Wolski K, (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170: 1191-1201 2010.207 [pii];10.1001/archinternmed.2010.207 [doi].
44. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471 NEJMoa072761 [pii];10.1056/NEJMoa072761 [doi].
45. Singh S, Loke YK, Furberg CD, (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195 298/10/1189 [pii];10.1001/jama.298.10.1189 [doi].